Welcome to HDMZ Connect, our monthly newsletter delivering the latest trends shaping science, biotech and healthcare — showcasing work that drives revenue, reputation, and investment for compelling brands — and offering an inside look at the award-winning culture behind it all.
In recent years, minimal residual disease (MRD) testing has burst onto the scene as a powerhouse in managing oncology care. Our own John Kang explores how this technology has evolved from a promising technology to an invaluable clinical tool, and the trends driving towards a potential golden age for MRD testing.
Agendia's FLEX Study Findings Showcase MammaPrint's Role in Guiding Chemotherapy Decisions
Genomic profiling is transforming how breast cancer is treated, helping to ensure that a patient’s care plan is tailored to the unique biology of their tumor. This enables doctors to make more precise treatment decisions – which is critical for avoiding both over- and undertreatment. Agendia's MammaPrint®, a genomic test that analyzes 70 genes, exemplifies this by classifying early-stage tumors into four categories of risk for recurrence. This provides clinicians and patients with data to make more informed choices about the necessity and duration of therapies like chemotherapy and extended endocrine therapy. Agendia recently announced findings from its ongoing FLEX study, which demonstrated MammaPrint's ability to predict the benefit of chemotherapy for patients with hormone receptor-positive, HER2-negative early-stage breast cancer.
Every year, HDMZers from around the world gather in Chicago for two days of professional development, team building, and community service. Check out some memorable moments from this year’s event!
